Bio-Bridge Science Signs Cooperative Agreement with Chinese Academy of Medical Sciences for Vaccine Development

  
    
  
  
    
      Bio-Bridge Science, Inc. (OTCBB: BGES) announced today that it has 
      entered into a cooperative agreement with the Institute of Basic Medical 
      Sciences at the Chinese Academy of Medical Sciences, a leading medical 
      research institute in China, to research and develop a human 
      papillomavirus polyvalent vaccine using prokaryotic expression system. 
      This vaccine is designed to prevent from infection by human 
      papillomavirus types 6, 11, 16, 18, 31, 45, and 58, which is expected to 
      provide broader protection than the current vaccine in the market and 
      have much lower production costs. Under the agreement, Bio-Bridge has 
      been granted the preferential right to develop the vaccine and enjoys a 
      60% interest in the project.
    
    
      Dr. Liang Qiao, Chairman and CEO of Bio-Bridge said, "We believe that 
      our agreement with the Chinese Academy of Medical Sciences will enable 
      us to solidify our research capability in China as we try to introduce 
      more potential vaccine products in addition to our current vaccine 
      pipeline. The Chinese Academy of Medical Sciences is a renowned medical 
      research institute and is the national level medical science research 
      center in China. We believe this cooperation will provide numerous 
      benefits to both parties.”
    
    
      About Chinese Academy of Medical Sciences
    
    
      The Chinese Academy of Medical Sciences was established in 1956 and is 
      the national level medical science research center in China. Its former 
      name was Peking Union Medical College, founded by the Rockefeller 
      Foundation in 1917. The Academy has 49 doctorate disciplines and 52 
      master disciplines, 4 national level laboratories, 8 minister level 
      laboratories and 6 post-doctor WHO research centers.
    
    
      Forward Looking Statements:
    
    
      This press release contains forward-looking statements as defined by the 
      Private Securities Litigation Reform Act of 1995. Forward-looking 
      statements include statements concerning plans, objectives, goals, 
      strategies, future events or performance, and underlying assumptions and 
      other statements that are other than statements of historical facts. 
      These statements are subject to uncertainties and risks including, but 
      not limited to, product and service demand and acceptance, changes in 
      technology, economic conditions, the impact of competition and pricing, 
      government regulation, and other risks defined in this document and in 
      statements filed from time to time with the Securities and Exchange 
      Commission. All such forward-looking statements, whether written or 
      oral, and whether made by or on behalf of the company, are expressly 
      qualified by these cautionary statements and any other cautionary 
      statements which may accompany the forward-looking statements. In 
      addition, the company disclaims any obligation to update any 
      forward-looking statements to reflect events or circumstances after the 
      date hereof. Please refer to SEC filings for additional information.